当前位置:首页 >> 基础医学 >>

Glutathione S-transferase Gene Polymorphisms and Risk and


NIH Public Access
Author Manuscript
Cancer. Author manuscript; available in PMC 2007 June 15.
Published in final edited form as: Cancer. 2007 March 1; 109(5): 840–848.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Glutathione S-transferase Gene Polymorphisms and Risk and Survival of Pancreatic Cancer
Li Jiao, MD, PhD1, Melissa L. Bondy, PhD2, Manal M. Hassan, PhD1, David Z. Chang, MD1, James L. Abbruzzese, MD1, Douglas B. Evans, MD3, Michael H. Smolensky, PhD4, and Donghui Li, PhD1 1Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 3Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 4Division of Environmental and Occupational Health, The University of Texas School of Public Health, Houston, Texas.

Abstract
BACKGROUND—Pancreatic cancer is a multifactorial disease with metastasis-prone and therapyresistant nature. The authors hypothesized that genetic variants of glutathione S-transferase (GST) affect detoxification of carcinogens and anticancer agents in the human pancreas and, thus, the risk and survival of pancreatic cancer. METHODS—Genotypes of GSTM1, GSTT1, and GSTP1 were determined in 352 patients with pancreatic ductal adenocarcinoma and in a control group of 315 healthy, non-Hispanic whites (frequency-matched by age and sex). Survival analysis was performed in a subset of 290 patients. Epidemiological and clinical information was obtained. A multiple unconditional logistic regression model, a Cox proportional hazards model, and log-rank tests were used for statistical analysis. RESULTS—No significant main effects of any of 3 GST genes on the risk of pancreatic cancer were observed. Subgroup analysis showed that older individuals (aged 62 years) who carried the GSTP1*C (105Val-114Val) containing genotype tended to have a reduced risk compared with younger individuals who carried the non-*C genotype (for sex and pack-years of smoking, the adjusted odd ratio was 0.54; 95% confidence interval [95% CI], 0.29-1.02). In a survival analysis of 138 patients who received 5-flurorouracil, patients who carried the GSTP1*C containing genotype had a significantly longer survival than patients who carried the non-*C genotype (multivariate hazard ratio, 0.45; 95% CI, 0.22-0.94). CONCLUSIONS—The GSTP1*C variant conferred a possible protective effect against pancreatic cancer in older individuals and a significant survival advantage in patients who received 5-florouracil. The current findings must be confirmed before further inferences can be made. Keywords glutathione S-transferase M1 (GSTM1); GSTT1; GSTP1; polymorphism; haplotype; risk; survival; pancreatic cancer

Address for reprints: Donghui Li, PhD, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030; Fax: (713) 834-6153; E-mail: dli@mdanderson.org Supported by National Institutes of Health grants CA84581 and CA98380, National Institute of Environmental Health Sciences Center grants P30 ES07784, National Institutes of Health Cancer Center Support (Core) grants CA16672, and a research grant from The University of Texas M. D. Anderson Cancer Center.

Jiao et al.

Page 2

It is estimated that, in 2006, approximately 33,730 Americans will develop pancreatic cancer, and 32,300 will die from this disease.1 The mortality rate of pancreatic cancer (10.5 per 100,000 population) is almost equal to its incidence rate (11.0 per 100,000 population) for both sexes and all ethnic groups.2 Cigarette smoking is the only established environmental risk factor for pancreatic cancer. Very little is known about how genetic and environmental factors interact to foster the development of this malignancy.3 Clinically, treatment of pancreatic cancer remains a challenge, and there is great heterogeneity in the way patients respond to chemotherapy. Therefore, it is important to understand how genetic factors contribute to both predisposition to and clinical outcome of this disease. The cytosolic glutathione S-transferases (GSTs) (Enzyme Commission no. 2.5.1.18) are a family of phase II isoenzymes that are important parts of the cell defense against numerous harmful chemicals that are produced endogenously and exogenously. GSTs catalyze the addition of reduced glutathione (GSH) to a variety of electrophilic compounds, including tobacco carcinogens4-6 and anticancer agents.7 Eight families of soluble GSTs in humans have been identified,8 and they have overlapping substrate specificities. GST-μ,GST-Θ, and GSTπ are encoded by the GSTM1, GSTT1, and GSTP1 genes, respectively; and these 3 genes have been examined extensively in association with genetic susceptibility9,10 and clinical outcomes of several types of human cancer.11-15 Homozygous deletion of the GSTM1 and GSTT1 genes (null genotype) has been associated with the loss or lack of enzyme activity and increased vulnerability to cytogenetic damage.16,17 It has been shown that the exon 5 A1404G, which encodes an isoleucine (Ile)→valine (Val) exchange at codon 105 (Ile105Val) (reference single nucleotide polymorphism [rs] no. 947894), and exon 6 C2294T, which encodes an Ala→Val exchange at codon 114 (Ala114Val) (rs no. 1799811) of the GSTP1 gene, confer lower levels of metabolizing activity toward a variety of carcinogens and anticancer agents.18-20 GSTμ,GST-Θ,and GST-π all are expressed in the human gastrointestinal tract.21 In particular, GSTπ appears to be one of the constitutive elements of the human pancreas.22 In the current study, we investigated the association between GST gene polymorphisms and the risk of pancreatic cancer as well as the clinical outcome of patients with cancer. We hypothesized that these polymorphisms influence the detoxification of carcinogens, reactive oxygen species, and anticancer drugs, thereby influencing susceptibility to pancreatic cancer as well as the clinical outcome of patients.23

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

MATERIALS AND METHODS
Study Population We investigated the association between polymorphisms and pancreatic cancer risk in a hospital-based, case-control study. Patients and controls were recruited consecutively from January 20, 2000 to December 20, 2004. Patients with pathologically confirmed primary pancreatic ductal adenocarcinoma (International Classification of Diseases for Oncology code C25.3; World Health Organization, 2000) were recruited from the Gastrointestinal Center at The University of Texas M. D. Anderson Cancer Center (M. D. Anderson). Controls were healthy, cancer-free individuals who were recruited from friends and genetically unrelated family members (usually spouses or in-laws) of patients who were diagnosed with cancers other than pancreatic cancer. No study participants had a prior history of cancer (except for nonmelanoma skin cancer). Patients and controls were frequency-matched by age, sex, and race. Informed consent to participate in interviews and to provide a blood sample was obtained from each participant. The study was approved by the M. D. Anderson Institutional Review Board.

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 3

During the study period, 561 potential patients were approached, and 442 patients (78.8%) consented to participate in the study. Fifty-one of those 442 patients (11.5%) were excluded because they failed to donate a blood sample after signing their informed consent. In total, 483 potential controls were approached, and 372 individuals (77.0%) consented to participate in the study. Fifteen of those 372 controls (4.0%) were excluded because of incomplete questionnaire data. Consequently, 391 patients and 357 controls met the eligibility criteria. Because of the known ethnic variations in pancreatic cancer risk and genotype distribution, the case-control analysis was focused on non-Hispanic white individuals only, including 352 patients (90.0%) and 315 controls (88.2%). Survival analysis was conducted among 290 nonHispanic white patients who received chemotherapy or chemoradiation at M. D. Anderson, and their complete medical records were available. Exposure and Clinical Data Collection Information on demographics and smoking exposure was collected by personal interview using a structured questionnaire, as described previously.24 The participants were classified as eversmokers or never-smokers according to whether they had ever smoked >100 cigarettes in their lifetime. Cumulative smoking exposure was estimated in pack-years, which were based on the average number of daily cigarette intake and the number of years smoked. Clinical information of 290 patients was abstracted from the patients’ medical records, as described previously.25 A comprehensive medical record review was performed to obtain information on neoadjuvant and/or adjuvant chemotherapy/chemoradiation for patients with resectable tumors and on first- and second-line definitive treatments for patients with unresectable tumors. None of these patients underwent tumor resection before they came to M. D. Anderson. Treatment regimens during the entire disease process were collapsed into 3 groups: 1) gemcitabine (GEM)-cisplatin (CDDP) (including oxaliplatin)-based therapy, including GEM/CDDP alone or followed by GEM/radiation; 2) GEM-based therapy, including GEM alone, GEM/radiation, and GEM/investigational agents; and 3) 5-fluorouracil (5-FU)based therapy, including 5-FU/radiation, 5-FU/other agents, and 5-FU/other agents/radiation. The majority of patients who received 5-FU (88%) received concurrent radiotherapy. Capecitabine, 1 of the synthesized 5-FU prodrugs, was the most common agent administered in 5-FU-based therapy (received by approximately 95% of patients). Treatment was started within 1 month of pathologic diagnosis of pancreatic cancer. Survival Measurement The subset of 290 patients was followed through December 30, 2005. The primary endpoint was overall survival (OS) duration from the date of pathologic diagnosis of pancreatic cancer to the date of death from any cause. Patients who were alive at the end of the study period were censored on the last date of follow-up. Each patient’s vital status was obtained and crosschecked with at least 1 of the following: inpatient medical record, the M. D. Anderson Tumor Registry, and the Social Security Death Index.25 Genotyping Genomic DNA was extracted from peripheral blood mononuclear cells that were obtained from the participants by using the Qiagen DNA isolation kit (Qiagen, Valencia, CA). The DNA aliquot was stored at 4°C for immediate use. GSTM1 and GSTT1 null genotypes were identified by using multiplex polymerase chain reaction, as described previously.26 The experiment reagents were purchased from PGC Scientifics (Frederick, MD). The GSTP1 polymorphisms were identified by using the Masscode system (BioServe Biotechnologies, Ltd., Laurel, MD). We analyzed a random 10% of samples in duplicate for quality control. Any discrepancy in genotype calls (0.2% of the duplicate) was resolved by using additional genotyping.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 4

Unsuccessful genotyping occurred most often in GSTP1 assays (<6% of samples) and was caused by inadequate quality or quantity of DNA.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Statistical Analyses The Intercooled Stata 9.0 software program (Stata Corporation, College Station, TX) and SPSS 12.0 software (SPSS Inc., Chicago, IL) were used for statistical analyses. All of the statistical tests were 2-tailed, and P values ≤.05 were considered statistically significant. The Pearson chi-square test was used to examine differences in the distribution of the risk factors and genotypes between patients and controls. The SNPAlyze software program (DYNACOM Company, Ltd., Mobara, Japan) was used to test for Hardy-Weinberg equilibrium of GSTP1 genotypes and linkage disequilibrium of the 2 alleles. The effect of different allele combinations of the GSTP1 gene was evaluated by using haplotype analysis. Haplotypes were reconstructed from the genotype data by using the PHASE software program (version 2).27 A diplotype (combined genotype) was assigned for each participant. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated by using an unconditional logistic regression model to examine the association between genotype and pancreatic cancer risk. Potential confounding factors were adjusted in the multivariate model when relevant (ie, when their removal from the multivariate model caused the β parameter estimates to change by >10%). Potential multiplicative interactions between gene-gene, gene and age (<62 years vs ≥62 years; 62 years was the median age in the control group), smoking (never-smoker vs ever-smoker), and pack-years of smoking (light smoker vs heavy smoker; the median number of pack-years in ever-smokers among controls was used as the cut-off point) were explored by generating a cross-product term in the unconditional logistic regression models. The likelihood-ratio test was used to test the significance of the interaction term in the models. Survival curves were estimated using the Kaplan-Meier product-limit method. Differences in the survival curves were tested by using the log-rank test. Factors that showed a significant effect on survival in the log-rank test were included in the multivariate Cox proportional hazards model to estimate hazard ratios (HRs) and the 95% CIs. Stratified analyses were performed to evaluate the association between genotypes and OS by age, sex, tumor resection, clinical stage, and treatment modality, as defined beforehand. Bonferroni correction was used to adjust the statistical significance level when multiple testing was performed in which α = . 05/k, with k equal to the number of independent hypotheses tested.

RESULTS
Characteristics of the Study Participants There were no significant differences in distribution according to age (10-year intervals) or sex between patients and controls (P .37 and P .40, respectively). The mean age was 61.7 years =(range, 37-87 years) for patients and 61.4 years (range, 32-88 years) for controls. Women accounted for 43.8% and 47.0% of patients and controls, respectively. Ever-smokers were more prevalent among patients (62.5%) than among controls (53.3%; P = .02), with an unadjusted OR of 1.46 (95% CI, 1.06-2.01). The prevalence of heavy smoking (≥22 pack-years) was 38.1% in patients and 27.0% in controls (P = .01; data not shown). Genotype and Haplotype Table 1 shows the genotype distribution in patients and controls. The prevalence of the genotype or variant allele was within the ranges commonly reported in whites of European ancestry.28,29 The GSTP1 genotype distribution was in Hardy-Weinberg equilibrium in both patients and controls (P > .30). Ile105Val and Ala114Val were in complete linkage
Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 5

disequilibrium (P < .0001; D′ = 1.0 for both patients and controls). Three haplotypes putatively were inferred—105Ile-114Ala (65.9%), 105Val-114Ala (25.9%), and 105Val-114Val (8.2%)— which corresponded to the GSTP1*A, GSTP1*B, and GSTP1*C alleles, respectively.19,30 The GSTP1*D allele (105Ile-P114Val) was not found in our study population. The haplotype distribution did not differ between patients and controls (P = .64). Six diplotypes (variant combinations) were reconstructed: GSTP1 *A/*A, *A/*B, *A/*C, *B/*B, *B/*C, and *C/*C. It is noteworthy that the GSTP1*A/*C diplotype was related to a lower risk of pancreatic cancer compared with the GSTP1*A/*A diplotype (OR, 0.62; 95% CI, 0.37-1.03) (Table 1). We defined the genotype as GSTP1*C-containing if the 105Val-114Val allele combination was present; we classified all other genotypes as non-GSTP1*C reference genotypes.29 Potential GSTP1 Polymorphism and Age Interaction in the Risk-association Study We observed a potential interaction between age and the GSTP1 Ile105Val polymorphism in modifying the risk of pancreatic cancer (Pinteraction = .05) (Table 2). Furthermore, older individuals (aged ≥62 years) who carried the GSTP1*C (105Val-114Val)-containing genotype had a nonsignificant reduced risk of pancreatic cancer compared with younger individuals who carried the non-*C genotype (OR adjusted for sex and pack-years of smoking, 0.54; 95% CI, 0.29-1.02). The interaction effect between GSTP1*C and age also was not statistically significant (P = .22). Clinical Characteristics of the Patients The characteristics of the subset of 290 patients who were included in the survival analysis (age, sex, and smoking status) were similar to the characteristics of the entire patient group. Of those 290 patients, 84 patients (29.0%) had localized tumors, 51 patients (17.6%) had potentially resectable tumors, 94 patients (32.4%) had locally advanced tumors, and 61 patients (21.0%) had metastatic tumors. During the study period, 69.3% of the patients died, and the median survival duration was 11.8 months. The median follow-up duration for the surviving patients was 24.5 months. The log-rank test showed that female sex, tumor resected, earlystage disease (localized or potentially resectable vs locally advanced or metastatic), low baseline serum CA19-9 level (categorized by quartile distribution), and a good performance status (<3) were significant, positive prognostic factors for OS at an α = .05 level of significance. These factors were included in the Cox regression model to estimate the adjusted HR. Genotype and Survival According to Treatment Modalities We observed no statistically significant associations between any of the polymorphisms and the clinical characteristics, treatment modalities, or OS of patients (log-rank test; all P values ≥.40). Because the association between polymorphisms and OS did not differ according to the first-line or second-line therapy, the analysis was based on whether patients ever received GEM/CDDP-, GEM-, or 5-FU-based therapy (Table 3). Among the patients who received GEM/CDDP-based treatment, GSTP1 Val105Val carriers had a longer median survival time (MST) than patients who carried the other 2 genotypes (logrank test; P= .02). In the patients who received GEM-based treatment, the GSTP1 114Val carriers survived significantly shorter than the Ala114Ala carriers (log-rank test; P= .02). However, the associations were not statistically significant after other clinical predictors were considered. The GSTP1 Ile105Val polymorphism was associated significantly with OS in 138 patients who received 5-FU-based therapy. The MST was 15.8 months (95%CI, 13.1-20.9 months) for patients who carried the Ile/Ile genotype, 22.2 months (95%CI, 16.0-37.9 months) for patients who carried the Ile/ Val genotype, and 35.8 months (95%CI, 14.4 months to not achieved) for patients who carried the Val/Val genotype (log-rank test; P .02) (Fig 1A). Compared with the Ile105Ile genotype, the adjusted HR was 0.64 (95% CI, 0.38-1.09; P= .06)
Cancer. Author manuscript; available in PMC 2007 June 15.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Jiao et al.

Page 6

for the Ile105Val genotype and 0.40 (95% CI, 0.18-0.89; P= .015) for the Val105 Val genotype. The GSTP1 Ile105Val polymorphism had no effect on OS in patients who did not receive 5FU (Fig.1B). Furthermore, the GSTP1*C carriers survived significantly longer than patients who carried the non-*C genotypes (adjusted HR, 0.45; 95% CI, 0.22-0.94; P= .025) (Table 3). However, after Bonferroni correction for multiple testing, the different survival function by GSTP1 genotype (*C vs non-*C) was not statistically significant (P = .025) at an α level of . 17 (α = .05/3, assuming 3 independent hypotheses because of 3 treatment regimens). Tumor resection, tumor stage, the GSTP1 Ile105Val polymorphism, and the serum CA19-9 level remained significant independent prognostic factors for survival among the patients who received 5-FU. There was no significant interactive effect between GSTP1 polymorphisms and smoking status or pack-years of smoking. In addition, there was no suggestive association between GSTM1 and GSTT1 genotypes and the risk or survival of pancreatic cancer, either in combination with other polymorphisms or with other exposure factors (data not shown).

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

DISCUSSION
To our knowledge, this study is the first to suggest a role of GSTP1 polymorphisms in pancreatic pathogenesis. We observed that the GSTP1*C allele potentially was related to a reduced risk of pancreatic cancer in older individuals and was associated significantly with a reduced hazard of dying in patients who received 5-FU-based treatment. It is unlikely that the GSTM1 and GSTT1 null genotypes play a major role in pancreatic pathogenesis. Individuals with reduced GST enzymatic activity may be at a greater risk for cancer because of decreased detoxification of tobacco carcinogens. Results from a previous study on pancreatic cancer indicated an interaction between the GSTT1 null genotype and heavy smoking in risk modification.31 Despite the finding in the current study that smoking is a significant risk factor for pancreatic cancer, we did not detect any gene-smoking interaction effect. Instead, we observed a nonsignificant, negative association between the risk of pancreatic cancer and the presence of the GSTP1*C allele exclusively in older individuals. The GSTP1*C variants encode the amino acids 105Val [in the central part of the hydrophobic substrate binding site (H site)] and 114Val (at the beginning of helix 5 outside the H site). Such amino acid substitutions may limit free access of the substrate to the H site, the efficient conjugation with glutathione, and the thermostability of the enzyme.32,33 Several studies have reported an age-specific effect of the GSTP1 polymorphism on the risk of cancer.34,35 The underlining biologic mechanism remains unclear. The possible interaction between age and GSTP1 genotype should be interpreted with caution. Previous studies of the association between GSTP1 polymorphisms and cancer risk generated mixed results.36-38 The discrepancy may be explained in part by the variations in study size, control selection, and genotyping methods as well as by different levels of metabolizing activity conferred by particular alleles toward the electrophilic compounds that are major etiologic agents in certain organs. Using various study systems, it has been shown that different GSTP1 alleles have different degrees of protection against the cytotoxicity of different anticancer agents.39 For example, the GSTP1*A allele has significantly higher activity against 1-chloro-2,4-dinitrobenzene,19 thiotepa,39,40 and chlorambucil41; whereas GSTP1*B and GSTP1*C have higher conjugation activity toward cisplatin, carboplatin,39 and epoxides of benzo[a]pyrene.42 Expression of GST-π is up-regulated significantly in pancreatic adenocarcinoma,43 indicating its potential role in acquired resistance to certain anticancer drugs. Among the various anticancer agents involved in pancreatic cancer treatment, CDDP is the only one shown to be the substrate for GST-π. However, we did not observe that GSTP1 polymorphisms modified the survivorship of patients who received CDDP-based therapy, but we did observe a reduced hazard of dying

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 7

associated with the GSTP1*C variant allele in patients who received 5-FU or 5-FU after CDDP. Although capecitabine is a 5-FU prodrug that undergoes complex metabolic pathways and nuclear transport activity before exerting its cytotoxic activity,44 no established data have demonstrated that GSTs are involved in the conjugation of 5-FU and its intermediate metabolites. Nevertheless, results from a previous study indicated an increased survival associated with the GSTP1 105Val variant in patients with advanced colorectal cancer who received 5-FU/oxaliplatint.12 Results from another study45 indicated an increase in GST-π expression in human gastrointestinal cancer cells after sequential administration of CDDP and 5-FU. The same study45 also showed that resistance of a gastrointestinal cancer cell line to 5FU was related to the expression of multidrug resistance-associated protein. Multidrug resistance-associated protein and GST-π are common cofactors in drug resistance. Goto et al. 46 demonstrated that GSH and GST-π are not important to the intracellular metabolism of 5FU; however, those authors observed nuclear GST-π accumulation in cancer cells in response to treatment with several anticancer drugs, including 5-FU. This evidence lent some indirect support to the association between GSTP1 polymorphisms and survival in patients who received treatment with 5-FU. We speculated that the GSTP1*C allele may affect cellular sensitivity to 5-FU through the drug-resistance mechanism. GST-π is a known regulator of the activity of Jun N-terminal kinase (JNK), which is activated transiently in response to oxidative stress.47 The *C allelic variant may interfere with the regulatory role of GST-π on JNK activity and, ultimately, in the modulation of apoptosis, depending on the redox status of the cell.32 Another possibility is that the GSTP1 gene polymorphisms are in linkage disequilibrium with other nearby genes that determine the biologic properties of 5-FU. In the current study, we failed to demonstrate any effect of GSTM1 and GSTT1 polymorphisms on pancreatic cancer risk and survival either individually or in combination with other factors. The lack of an association with risk was consistent with previous findings.48,49 The predominant expression of GST-π in pancreatic cells may explain why polymorphisms ofGSTP1, but not of GSTM1 or GSTT1, exerted certain effects on risk and survival of pancreatic cancer in this study.50,21 Alternatively, deficiency of an individual GST-l and GSTΘ isoenzyme may be compensated by other isoforms. We may have missed weak effects conferred by GSTM1 and GSTT1 polymorphisms, because our genotyping assay could not distinguish between wild-type and heterozygous individuals.51 Our survival analysis was limited in a number of ways. 1) Although we adjusted significant predictors of clinical outcome of pancreatic cancer in the multivariate models, we do not know whether residual confounding effects of tumor resection or tumor stage or uncontrolled effects of multiple chemotherapy agents or nutritional status would bias the study observations. 2) We were unable to monitor the cytotoxic effects in patients who received chemotherapy. Indeed, clinical outcomes reflect the balance of the drug response of cancer cells and cytotoxic effects on normal cells. 3) It is not feasible to evaluate GST expression at the messenger RNA or protein levels or enzyme activity in the pancreas during the course of treatment. Therefore, genotype and phenotype associations cannot be established. 4) After Bonferroni correction for multiple testing, the association between the GSTP1*C allele and survival in patients who received treatment with 5-FU was not statistically significant. Therefore, the preliminary finding from this hypothesis-generating study must be replicated in other studies. 5) Our observations were made among non-Hispanic white patients and may not be applicable to other ethnic groups. In summary, in this report, we have data suggesting that genetic polymorphisms of GSTP1 may be among the mechanisms that modify the risk of pancreatic cancer in older individuals and affect the survival of patients who receive 5-FU-based treatment. Because our major findings were based on post-hoc hypotheses, they must be confirmed in larger, wellcharacterized populations. Both risk and survival are phenotypic consequences of the interplay
Cancer. Author manuscript; available in PMC 2007 June 15.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Jiao et al.

Page 8

of multiple genes in different pathways. Further in-depth studies will be required to improve our understanding of the roles of genetic variations and molecular regulatory machineries of GST-π and other players in pancreatic cancer development and clinical management.
Acknowledgements We thank the study participants. We acknowledge Yingqiu Du, Ping Chang, Jijiang Zhu, Yanan Li, and Cynthia Zhang for the laboratory work and Rabia Khan, Kaustubh Mestry, Ajay Nooka, and Hui Liu for the fieldwork. We also thank the clinical staff for their assistance with patient recruitment. and Don Norwood for scientific editing.

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

REFERENCES
1. American Cancer Society. Cancer Facts and Figures: 2006. American Cancer Society; Atlanta, Ga: 2006. 2. Ries, L.; Eisner, M.; Kosary, C.; Hankey, B.; Miller, B.; Clegg, L. SEER Cancer Statistics Review, 1975-2002. National Cancer Institute; Bethesda, Md: 2005. 3. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003;33:3–14. [PubMed: 12909734] 4. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51–88. [PubMed: 15822171] 5. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000;463:247–283. [PubMed: 11018744] 6. Salama SA, Abdel-Rahman SZ, Sierra-Torres CH, Hamada FA, Au WW. Role of polymorphic GSTM1 and GSTT1 genotypes on NNK-induced genotoxicity. Pharmacogenetics 1999;9:735–743. [PubMed: 10634136] 7. Tew KD, Monks A, Barone L, et al. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol 1996;50:149–159. [PubMed: 8700107] 8. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S-transferase family of enzymes. Mutat Res 2001;482(12):21–26. [PubMed: 11535245] 9. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733–743. [PubMed: 9298582] 10. Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ 1999:231–249. [PubMed: 10493261] 11. Yang G, Shu XO, Ruan ZX, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 2005;103:52–58. [PubMed: 15565566] 12. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002;94:936–942. [PubMed: 12072547] 13. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione Stransferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res 2005;11:2175–2179. [PubMed: 15788664] 14. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001;61:7130–7135. [PubMed: 11585745] 15. Okcu MF, Selvan M, Wang LE, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 2004;10:2618–2625. [PubMed: 15102663] 16. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000;61:154–166. [PubMed: 10971201] 17. Norppa H. Cytogenetic biomarkers and genetic polymorphisms. Toxicol Lett 2004;149(13):309–334. [PubMed: 15093278] 18. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998;8:27–31. [PubMed: 9511178]
Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 9

19. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997;272:10004–10012. [PubMed: 9092542] 20. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275–280. [PubMed: 9498276] 21. de Bruin WC, Wagenmans MJ, Peters WH. Expression of glutathione S-transferase alpha, P1-1 and T1-1 in the human gastrointestinal tract. Jpn J Cancer Res 2000;91:310–316. [PubMed: 10760690] 22. Coles BF, Anderson KE, Doerge DR, Churchwell MI, Lang NP, Kadlubar FF. Quantitative analysis of interindividual variation of glutathione S-transferase expression in human pancreas and the ambiguity of correlating genotype with phenotype. Cancer Res 2000;60:573–579. [PubMed: 10676639] 23. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487–491. [PubMed: 10521338] 24. Jiao L, Hassan MM, Bondy ML, Abbruzzese JL, Evans DB, Li D. The XPD Asp(312)Asn and Lys (751)Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett. Feb 1;2006 [Epub ahead of print] 25. Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006;24:1720–1728. [PubMed: 16520463] 26. Xiong P, Bondy ML, Li D, et al. Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a casecontrol study. Cancer Res 2001;61:8465–8469. [PubMed: 11731429] 27. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–989. [PubMed: 11254454] 28. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239–1248. [PubMed: 11751440] 29. Maugard CM, Charrier J, Pitard A, et al. Genetic polymorphism at the glutathione S-transferase (GST) P1 locus is a breast cancer risk modifier. Int J Cancer 2001;91:334–339. [PubMed: 11169956] 30. Lo HW, Antoun GR, Ali-Osman F. The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. Cancer Res 2004;64:9131–9138. [PubMed: 15604283] 31. Duell EJ, Holly EA, Bracci PM, Liu M, Wiencke JK, Kelsey KT. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002;94:297–306. [PubMed: 11854392] 32. Bernardini S, Bellincampi L, Ballerini S, et al. Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem 2005;51:944–951. [PubMed: 15805147] 33. Johansson AS, Stenberg G, Widersten M, Mannervik B. Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105. J Mol Biol 1998;278:687–698. [PubMed: 9600848] 34. Gaspar J, Rodrigues S, Gil OM, et al. Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genet Cytogenet 2004;151:60–67. [PubMed: 15120911] 35. Wang Y, Spitz MR, Schabath MB, Ali-Osman F, Mata H, Wu X. Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. Lung Cancer 2003;40:25–32. [PubMed: 12660004] 36. Chan QK, Khoo US, Ngan HY, et al. Single nucleotide polymorphism of pi-class glutathione Stransferase and susceptibility to endometrial carcinoma. Clin Cancer Res 2005;11:2981–2985. [PubMed: 15837751] 37. Hashibe M, Brennan P, Strange RC, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1509–1517. [PubMed: 14693745]

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 10

38. Cao W, Cai L, Rao JY, et al. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer 2005;104:2400–2408. [PubMed: 16240451] 39. Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 2002;12:543–553. [PubMed: 12360105] 40. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999;366:89–94. [PubMed: 10334868] 41. Pandya U, Srivastava SK, Singhal SS, et al. Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 2000;278:258–262. [PubMed: 11071881] 42. Hu X, Herzog C, Zimniak P, Singh SV. Differential protection against benzo[a]pyrene-7,8dihydrodiol-9,10-epoxideinduced DNA damage in HepG2 cells stably transfected with allelic variants of pi class human glutathione S-transferase. Cancer Res 1999;59:2358–2362. [PubMed: 10344744] 43. Trachte AL, Suthers SE, Lerner MR, et al. Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg 2002;184:642–647. [PubMed: 12488200]discussion, 647-648 44. Martino R, Malet-Martino M, Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr Drug Metab 2000;1:271–303. [PubMed: 11465049] 45. Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999;5:2620–2628. [PubMed: 10499641] 46. Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anticancer drugs. Jpn J Cancer Res 2002;93:1047–1056. [PubMed: 12359059] 47. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25:1639–1648. [PubMed: 16550164] 48. Bartsch H, Malaveille C, Lowenfels AB, Maisonneuve P, Hautefeuille A, Boyle P. Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:-quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. Eur J Cancer Prev 1998;7:215–223. [PubMed: 9696930] 49. Liu G, Ghadirian P, Vesprini D, et al. Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer 2000;82:1646–1649. [PubMed: 10817498] 50. Collier JD, Bennett MK, Hall A, Cattan AR, Lendrum R, Bassendine MF. Expression of glutathione S-transferases in normal and malignant pancreas: an immunohistochemical study. Gut 1994;35:266– 269. [PubMed: 8307481] 51. Moore LE, Huang WY, Chatterjee N, et al. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2005;14:1823–1827. [PubMed: 16030123]

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 11

NIH-PA Author Manuscript NIH-PA Author Manuscript
FIGURE 1.

The probability of survival is illustrated according to the presence of the glutathione Stransferase P1 (GSTP1) isoleucine (Ile)→valine (Val) exchange at codon 105 (Ile105Val) polymorphism in patients who received 5-fluorouracil (5-FU)-based chemotherapy/ chemoradiation (A) and patients who received therapies other than 5-FU (B). P values were determined from log-rank tests.

NIH-PA Author Manuscript

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 12

TABLE 1

Distribution of Glutathione S-transferase Genotypes in Pancreatic Cancer Patients and Controls
No. (%)

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

Genotype GSTM1 ?Wild type ?Null GSTT1 ?Wild type ?Null GSTP1 Ile105Val ?Ile/Ile ?Ile/Val ?Val/Val ?Ile/Val and Val/Val ?Val allele frequency GSTP1 Ala114Val ?Ala/Ala ?Ala/Val ?Val/Val ?Ala/Val and Val/Val ?Val allele frequency GSTP1 diplotype* ?*A/*A ?*A/*B ?*A/*C ?*B/*B ?*B/*C ?*C/*C

Patients (n = 352)

Controls (n = 315)

Unadjusted OR [95% CI]

187 (54.0) 159 (46.0) 271 (78.6) 74 (21.4) 151 (44.7) 141 (41.7) 46 (13.6) 187 (55.3) 0.34 286 (85.4) 46 (13.7) 3 (0.9) 49 (14.6) 0.08 161 (45.8) 117 (33.2) 32 (9.1) 25 (7.1) 14 (4.0) 3 (0.8)

157 (49.8) 158 (50.2) 248 (78.7) 67 (21.3) 117 (39.3) 146 (49.0) 35 (11.7) 181 (60.7) 0.36 242 (81.2) 55 (18.5) 1 (0.3) 56 (18.8) 0.10 127 (40.3) 113 (35.9) 41 (13.0) 19 (6.0) 14 (4.5) 1 (0.3)

1.00 0.84 [0.62-1.16] 1.00 1.01 [0.68-1.49] 1.00 0.75 [0.54-1.04] 1.02 [0.62-1.68] 0.80 [0.58-1.10] 1.00 0.71 [0.46-1.08] 2.53 [0.26-24.6] 0.74 [0.49-1.13] 1.00 0.82 [0.58-1.16] 0.62 [0.37-1.03] 1.04 [0.55-1.97] 0.79 [0.36-1.71] 2.34 [0.24-23.0]

OR indicates odds ratio; 95% CI, 95% confidence interval; GST, glutathione S-transferase; GSTM1, GST M1 polymorphism; GSTT1, GST T1 polymorphism; GSTP1, GST P1 polymorphism; Ile, isoleucine; Val, valine; Ala, alanine. * A, 105Ile-114Ala; *B, 105Val-114Ala; *C, 105Val-P114Val.

Cancer. Author manuscript; available in PMC 2007 June 15.

Jiao et al.

Page 13

TABLE 2

Glutathione S-transferase P1 Polymorphisms and Age Interaction in Modifying Pancreatic Cancer Risk
Genotype Age, y No. of patients/controls Adjusted OR* P?

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

GSTP1 Ile105Val ?Ile/Ile ?Ile/Ile ?Ile/Val and Val/Val ?Ile/Val and Val/Val GSTP1 Ala114Val ?Ala/Ala ?Ala/Ala ?Ala/Val and Val/Val ?Ala/Val and Val/Val GSTP1 genotypes ?Non-*C ?Non-*C ?*C *C

<62 ≥62 <62 ≥62 <62 ≥62 <62 ≥62 <62 ≥62 <62 ≥62

57/57 89/57 93/79 89/101 128/109 158/133 29/26 20/30 135/119 168/140 29/26 20/30

1.00 1.61 (0.98-2.65) 1.20 (0.74-1.92) 0.92 (0.57-1.47) 1.00 0.99 (0.70-1.40) 0.94 (0.52-1.70) 0.52 (0.28-0.98) 1.00 1.04 (0.74-1.45) 0.98 (0.54-1.76) 0.54 (0.29-1.02)

.05

.22

.22

OR indicates odds ratio; GSTP1, glutathione S-transferase P1 polymorphism; Ile, isoleucine; Val, valine; Ala, alanine; *C, 105Val114Val. * ? ORs were adjusted for sex and for the number of smoking pack-years (continuous).

P value for likelihood ratio test for interaction between age (<62 years vs ≥62 years; 62 years was the median age in the control group) and GSTP1 polymorphisms.

Cancer. Author manuscript; available in PMC 2007 June 15.

TABLE 3

Glutathione S-transferase P1 Polymorphisms and Overall Survival by Treatment Modality in Patients With Pancreatic Cancer
GEM-based treatment P? 146 64 66 13 .02 122 .46 129 .30 17 15 11.8 .02 19 9 94 18.3 1.00 1.44 (0.80-2.61) 117 78 18 16 8.5 .02 18 9 90 18.3 118 76 79 62 16.2 .41 69 36 23.3 18.6 22.3 16.2 22.3 11 19.6 20 9 35.8 51 14.5 49 27 22.2 44 18.1 62 45 15.8 109 17 138 87 18.6 No. of patients P? No. of deaths MS, Months HR (95% CI)* No. of patients No. of deaths MS, Months HR (95% CI)* 5-FU-based treatment P?

GEM/CDDP-based treatment

Jiao et al.

Polymorphism

No. of patients

No. of deaths

MS, Months

HR (95% CI)*

150

105

15.9

Overall GSTP1105 ?Ile/Ile

62

45

16.2

?Ile/Val

56

42

12.8

27

15

24.5

83

57

14.4

1.00 1.06 (0.67-1.69) 0.74 (0.40-1.37) 0.99 (0.62-1.42)

1.00 1.03 (0.67-1.57) 0.92 (0.46-1.83) 1.00 (0.67-1.51)

118

83

15.9

25

16

14.5

1.00 106 (0.59-1.92)

1.00 1.58 (0.88-2.82)

?Val/Val ?Ile/Val and Val/Val GSTP1114 ?Ala/Ala ?Ala/Val and Val/Val GSTP1 genotype ?Non-*C

125

90

15.8

?*C

25

15

18.2

1.00 1.10 (0.60-2.30)

GEM indicates gemcitabine; CDDP, cisplatin; 5-FU, 5-fluorouracil; MS, medial survival; HR, hazard ratio; 95% CI, 95% confidence interval; GSTP1, glutathione S-transferase P1 polymorphism; Ile, isoleucine; Val, valine; ALA, alanine, *C, 105Val-114Val.

*

HRs were adjusted for sex, tumor resection, tumor stage, CA19-9 value, and performance status.

?

P value for log-rank test.

Cancer. Author manuscript; available in PMC 2007 June 15.

?

P = .025 (not significant at a Bonferroni-adjusted α level of .017).

NIH-PA Author Manuscript
1.00 0.64 (0.38-1.09) 0.40 (0.18-0.89) 0.56 (0.34-0.92) 1.00 0.45 (0.24-1.02) 1.00 0.45 (0.22-0.94)? .02 .24 .11

NIH-PA Author Manuscript
Page 14

NIH-PA Author Manuscript


相关文章:
非激素依赖性前列腺癌的蛋白组学研究和分子靶向研究-中华医学会_....doc
Association between glutathione S-transferases M1 16 and T1 gene polymorphisms and prostate cancer risk: a systematic review and meta-analysis. Androgen ...
谷胱甘肽S-转移酶P1基因多态性与支气管肺发育不良的关系研究_论文....pdf
谷胱甘肽S-转移酶P1基因多态性与支气管肺发育不良的关系研究_电子/电路_工程科技...HU X L Relationship of gene polymorphisms of glutathione Stransferase P1 ...
外科试验室近几年规划汇报_图文.ppt
Glutathione S-transferases T1 null genotype associates with susceptibility to ...Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic...
谷胱甘肽S-转移酶M1和T1基因多态性与白癜风易患性关系的Meta分析_....pdf
医学循 谷胱甘肽 S一转 移酶M1和T1基 因多态 性与 白癜 风易 患性 关系的...Glutathione Stransferase M1 and T1 Geneitc Polymorphisms and Viitifgo ...
Asthma and pregnancy-Nelson_图文.pdf
and Risk of Wheeze at Age 5 years According to Glutathione S Transferase ... and GSTP1 Polymorphisms GSTP1-01 AA(31%), Trend P=0.65 Prevalence ...
Genetic polymorphisms of glutathione S-transferase genes GSTM....pdf
Genetic polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and risk of CHD_医药卫生_专业资料。Mutagenesis Advance Access published March 30, 2010...
全院SCI汇总.xls
gene Wang Y, Liu YH, Ma HX, Fan WW, Miao polymorphisms with risk of ...glutathione transferase inhibitors Classification of plasmid vectors using ...
GSTP1-结直肠癌2009.pdf
genetic factors significantly associated with an increased risk of dying (HR ...Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue ...
Dedicated Glutathione S-Transferase Mediates Carbon....pdf
Genetic polymorphisms of... 5页 1财富值如要投诉违规内容,请到百度文库投诉... Dedicated Glutathione S-Transferase Mediates CarbonSulfur Bond Formation in ...
Genetic polymorphism of glutathione S-transferase T1 gene and....pdf
Genetic polymorphism of glutathione S-transferase T1 gene and susceptibility to idiopathic azoos_专业资料。维普资讯 http://www.cqvip.com Blkwelacl Pblhi...
Genetic polymorphism of glutathione-S-transferase M1 and T1 ....pdf
Genetic polymorphism of glutathione-S-transferase M1 and T1 in associated ...Genetic polymorphisms ... 32人阅读 9页 2.00 A Synonymous Polymorph....
Carmen J Marsit, PhD.pdf
Glutathione Stransferase polymorphisms and the synergy of alcohol and tobacco...Genetic variation in the vitamin C receptor, SLC23A2, modifies risk of ...
clpt2008261a.pdf
Gene Predicts Efficacy of Low-Dose Azathioprine for Patients With Systemic ...The contributions of gene polymorphisms of TPMT and glutathione-S transferase ...
药物代谢PPT Drug Metabolism 4_图文.ppt
Humans have 18 families of cytochrome P450 genes ...Polymorphisms cause differences in drug metabolism: ...Glutathione conjugation by Glutathione-S-transferase:...
ifngr1, gstt1, gstp1 s....pdf
(2014) 35:49834986 Gene family of glutathione S-transferase, in ...GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors, and ...
ij_图文.pdf
enzymes transporters Genetic polymorphisms Inger...Sulfotransferases X Glutathione S-transferases UDP ...High risk for ADRs ? No response from certain ...
CYP1A1, CYP2E1, and GSTM1 Gene Polymorphisms and ....pdf
CYP1A1, CYP2E1, and GSTM1 Gene Polymorphisms and Susceptibility to ...(2005) Glutathione S- transferase x x M1, T1, P1 genotypes and risk ...
Glutathione S-transferase M1 and glutathione S-transferase T1....pdf
Glutathione S-transferase M1 null genotype metaanalysis on gastric cancer risk...Glutathione S-transferase M1, T1 and P1 gene polymorphisms and the risk of...
Genetic analysison the association between polymorphisms of ....pdf
Genetic analysison the association between polymorphisms of UGT1A1 and GST ...(UGTIA1)e.211G>A and glutathione Stransferases irubinemia;Neonate Chinese...
外科室近几年规划汇报_图文.ppt
Glutathione S-transferases T1 null genotype associates with susceptibility to ...Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic...